Lilly Vancocin Discontinued: Inventory Distributed To CAPD Patients
Executive Summary
Lilly is working with FDA to set up a distribution program to provide the remaining inventory of Vancocin to CAPD patients following the company's decision to discontinue its injectable and oral solution vancomycin
You may also be interested in...
Lilly Forteo Labeling Talks Last Step Before Approval; GMP Issues Resolved
Lilly completion of Forteo labeling negotiations with FDA is the only remaining hurdle before final approval, following the resolution of manufacturing issues for the osteoporosis agent
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials